A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects (NCT07280013)
A Phase 1B, Open-label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma. The first part of the study will evaluate different dose levels of cemsidomide in combination with elranatamab in a limited number of subjects. Approximately 3 different dose levels of cemsidomide in combination with elranatamab may be explored. Once a dose level is determined safe, additional subjects may be enrolled through expansion of the dose level. This expansion will provide further exploration of the safety and evaluation of preliminary antimyeloma activity. Cemsidomide will be taken orally each cycle for 14 days on/14 days off (1 cycle=28 days). Elranatamab will be administered by subcutaneous injection twice a month. Dexamethasone will be administered weekly until a confirmed response but no longer than 4 cycles.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- UC Davis Comprehensive Cancer Center — Sacramento, California
- UCLA Health, Jonsson Comprehensive Cancer Center — Santa Monica, California
- University of Florida — Gainesville, Florida
- University of Miami — Miami, Florida
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- Loyola University Medical Center — Maywood, Illinois
- Indiana University — Indianapolis, Indiana
- Norton Cancer Institute St. Matthews — Louisville, Kentucky
- University of Maryland Greenbaum Comprehensive Cancer Center — Baltimore, Maryland
- START Midwest — Grand Rapids, Michigan
- University of Nebraska — Omaha, Nebraska
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
- Perlmutter Cancer Center at NYU Langone Hospital — Brooklyn, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Duke Cancer Center — Durham, North Carolina
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- Baylor University Medical Center — Dallas, Texas
- Houston Methodist Hospital — Houston, Texas
- Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (617) 231-0700
Email: clinicaltrials@c4therapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma (MM)
- Neurocognitive Trajectories After BCMA CAR-T — Charlotte, North Carolina
- MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma — Little Rock, Arkansas
- PET-Enabled Dual-Energy CT in Multiple Myeloma — Sacramento, California
- Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma — Maywood, Illinois
- A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma — Denver, Colorado
Explore by condition: All Multiple Myeloma (MM) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.